Clinical trials: Advanced Digestive System Tumor
Colon Cancer
Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer
The study was conducted on patients with advanced right-sided colon cancer, and the clinical pathological and prognostic data of the patients were compared between the two groups of patients who were randomly divided into those…
- Trial name
- BLARCC (NCT06709144)
- Testing
- SMA lymph node dissection, SMV lymph node dissection
- Where
- China
- Volunteers
- 896 people
- Sponsor
- Haixing Ju, MD
Neuroendocrine Tumor, Carcinoid Tumor
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
The purpose of this research study is to determine the safety of the combination of SOM230 and RAD001, as well as determine the highest dose of this combination that can be given to people safely.
- Conditions
- Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT00804336
- Testing
- SOM230, RAD001
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Gastrointestinal Stromal Tumors
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib.
- Trial name
- INTRIGUE (NCT03673501)
- Testing
- Ripretinib, Sunitinib
- Where
- 121 sites in United States, Argentina and 20 more
- Volunteers
- 453 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Colorectal Polyps
Discard:Characterisation of Colonic Polyps in Vivo
Prospective study of accuracy of colonic polyp characterisation in vivo using high resolution white light endoscopy, narrow band imaging and chromoendoscopy.
- Trial name
- DISCARD (NCT00888771)
- Where
- United Kingdom
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Esophageal Squamous Cell Carcinoma
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC
Tislelizumab combined with chemotherapy sequential neoadjuvant therapy for non-cCR patients after neoadjuvant chemoradiotherapy in locally advanced ESCC.
- Trial name
- ETNT (NCT05189730)
- Testing
- Tirelizumab, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Advanced Pancreatic Cancer
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination…
- Trial name
- ARC-8 (NCT04104672)
- Testing
- AB680, Zimberelimab, Nab-paclitaxel
- Where
- 9 sites in United States
- Volunteers
- 196 people
- Sponsor
- Arcus Biosciences, Inc.
Colorectal Cancer
A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.
This study will assess the efficacy and safety of treatment with the combination Avastin (bevacizumab) 5mg/kg iv every 2 weeks, Xeloda (capecitabine) 1000 mg po b.i.d.
- Trial name
- NCT01159171
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin
- Where
- 6 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine…
- Trial name
- VISTA-1 (NCT06824064)
- Testing
- RBS2418
- Where
- 5 sites in United States, Puerto Rico and 1 more
- Volunteers
- 150 people
- Sponsor
- Riboscience, LLC.
Metastatic Pancreatic Cancer
Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas
To evaluate the 6-month overall survival, safety, and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer.
- Trial name
- NCT00837031
- Testing
- Lenalidomide, Gemcitabine
- Where
- 9 sites in United States
- Volunteers
- 72 people
- Sponsor
- SCRI Development Innovations, LLC
Stomach Neoplasms, Hyperthermic Intraperitoneal Chemotherapy
Comparison of the Efficiency Between Intraoperative and Postoperative Hyperthermic Intraperitoneal Chemotherapy With Docetaxel Combine Oxaliplatin in Patients With Advanced Gastric Cancer
Advanced gastric cancer has always been the focus and difficulty in the treatment of gastric cancer, and postoperative peritoneal recurrence is one of the key factors with poor prognosis.
- Trial name
- NCT04522011
- Testing
- intraoperative or postoperative hyperthermic intraperitoneal chemotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Biliary Tract Cancers (BTC)
Cosiporfin Sodium for Injection Photodynamic Therapy
Study Design: Multicenter, open-label, Single Group Study Population: Patients with locally advanced or recurrent metastatic extrahepatic cholangiocarcinoma who are inoperable or unwilling to undergo surgery.
- Trial name
- DVDMS (NCT07398339)
- Testing
- Cosiporfin Sodium for injection, DVDMS, Gemcitabine Hydrochloride for Injection, Cisplatin for injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Guangsheng Biopharmaceutical Co., Ltd
Gastrointestinal Cancer
EAT-ING: Enhancing Anticancer Treatment Safety Via Immunomodulatory Nutritional Support in Advanced Gastrointestinal Cancers
The use of immunomodulants in patients with GI cancer has been progressively gaining attention in the last years, as a high-calorie-high-protein nutritional blend enriched in immunonutrients has shown efficacy in several studies…
- Trial name
- EAT-ING (NCT07590622)
- Testing
- LH BLU, ONS
- Volunteers
- 88 people
- Sponsor
- IRCCS San Raffaele
Colo-rectal Cancer
Total Neoadjuvant Treatment Without Surgery For Locally Advanced Rectal Cancer
NO-CUT is a one-stage phase II trial seeking to establish whether an oxaliplatin-based chemotherapy preceding standard neo-adjuvant fluoropyrimidines-based chemo radiotherapy, can safely spare demolitive surgical intervention in…
- Trial name
- NO-CUT (NCT03565029)
- Testing
- XELOX, Radiotherapy
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Niguarda Hospital
Colorectal Cancer
Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
This is a phase I/II multi-center open-label proof of concept study, consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of dacomitinib plus…
- Trial name
- M13DAP (NCT02039336)
- Testing
- Dacomitinib, PD-0325901, Docetaxel
- Where
- 3 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- The Netherlands Cancer Institute
Pancreatic Cancer, Exocrine Pancreatic Insufficiency
Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer
Malnutrition and cachexia are common in patients with advanced pancreatic ductal adenocarcinoma (PDAC) and have a significant influence on the tolerance and response to treatments.
- Conditions
- Pancreatic Cancer, Exocrine Pancreatic Insufficiency, Metastatic Pancreatic Cancer, Chemotherapy
- Trial name
- PAC-MAIN (NCT04112836)
- Where
- 8 sites in Italy, Romania and 4 more
- Volunteers
- 186 people
- Sponsor
- Moscow Clinical Scientific Center
Stomach Neoplasms, Gastric Cancer (Diagnosis)
Lymph Node Metastasis Pattern After Neoadjuvant Chemoimmunotherapy in LAGC
The purpose of this observational study is to learn how stomach cancer that has spread to nearby lymph nodes responds to standard chemotherapy combined with immunotherapy given before surgery.
- Conditions
- Stomach Neoplasms, Gastric Cancer (Diagnosis), Gastric Adenocarcinoma
- Trial name
- NCT07899775
- Testing
- Neoadjuvant SOX chemotherapy combined with PD-1 inhibitor
- Volunteers
- 103 people
- Sponsor
- Hainan General Hospital
Liver Cancer
Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00941967
- Testing
- gemcitabine hydrochloride, oxaliplatin, sorafenib tosylate
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Gastrointestinal Stromal Tumors
Ripretinib in Chinese Patients With Advanced GIST: a Real World Study
to evaluate the clinical efficacy, safety and predictive factors of ripetinib in Chinese patients with advanced GIST in the real world
- Trial name
- NCT05697107
- Testing
- Ripretinib Oral Tablet
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Peking University
Pancreatic Cancer
Study of Induction Chemotherapy Followed by Radiochemotherapy in Locally Advanced Pancreatic Cancer
There is no a clear consensus regarding the optimal treatment of locally advanced pancreatic disease. There is a potential role for neoadjuvant therapy to treat micrometastatic disease with chemotherapy, as well as for the…
- Trial name
- NCT02984501
- Testing
- Radiation, Chemotherapy
- Volunteers
- 41 people
- Sponsor
- Campus Bio-Medico University
Gastric Cancer, Adenocarcinoma of Esophagogastric Junction
TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
This is a prospective one arm phase II clinical study to evaluate the efficacy and safety of TQB2450 (PD-L1 inhibitor), anlotinib combined with oxaliplatin and capecitabine in patients with unresectable locally advanced…
- Trial name
- NCT04891900
- Testing
- TQB2450/Anlotinib hydrochloride/Oxaliplatin/Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Henan Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.